8.97
price up icon5.04%   0.43
after-market Handel nachbörslich: 8.97
loading
Schlusskurs vom Vortag:
$8.54
Offen:
$8.62
24-Stunden-Volumen:
1.09M
Relative Volume:
1.01
Marktkapitalisierung:
$449.94M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.7053
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
-9.03%
1M Leistung:
-4.68%
6M Leistung:
-9.58%
1J Leistung:
-36.43%
1-Tages-Spanne:
Value
$8.43
$9.29
1-Wochen-Bereich:
Value
$8.43
$9.83
52-Wochen-Spanne:
Value
$5.035
$15.36

Regenxbio Inc Stock (RGNX) Company Profile

Name
Firmenname
Regenxbio Inc
Name
Telefon
240-552-8181
Name
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Name
Mitarbeiter
353
Name
Twitter
@REGENXBIO
Name
Nächster Verdiensttermin
2025-03-04
Name
Neueste SEC-Einreichungen
Name
RGNX's Discussions on Twitter

Vergleichen Sie RGNX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RGNX
Regenxbio Inc
8.97 494.58M 89.04M -241.08M -194.72M -5.26
Biotechnology icon
ONC
Beone Medicines Ltd Adr
246.68 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.09 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 40.37M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
605.39 64.44B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
77.49 6.19B 0 -153.72M -103.81M -2.00

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-11 Herabstufung Goldman Buy → Neutral
2025-02-07 Fortgesetzt Raymond James Outperform
2024-11-15 Fortgesetzt Morgan Stanley Overweight
2024-10-10 Fortgesetzt Raymond James Outperform
2024-06-07 Eingeleitet Goldman Buy
2024-03-11 Eingeleitet H.C. Wainwright Buy
2024-03-08 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-03-06 Hochstufung Leerink Partners Market Perform → Outperform
2024-02-21 Fortgesetzt Raymond James Outperform
2023-11-01 Eingeleitet Stifel Buy
2023-06-02 Eingeleitet Robert W. Baird Outperform
2022-06-23 Eingeleitet Berenberg Buy
2021-12-15 Eingeleitet Wedbush Neutral
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2021-01-06 Hochstufung Raymond James Outperform → Strong Buy
2020-12-16 Eingeleitet UBS Buy
2020-06-25 Fortgesetzt BofA/Merrill Buy
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2019-08-20 Hochstufung SVB Leerink Underperform → Mkt Perform
2019-06-18 Bestätigt Chardan Capital Markets Buy
2019-06-14 Fortgesetzt Raymond James Outperform
2019-06-05 Bestätigt Chardan Capital Markets Buy
2019-02-25 Hochstufung Evercore ISI In-line → Outperform
2019-02-05 Hochstufung Raymond James Outperform → Strong Buy
2018-12-17 Bestätigt Chardan Capital Markets Buy
2018-11-08 Bestätigt BofA/Merrill Neutral
2018-08-08 Bestätigt Chardan Capital Markets Buy
2018-07-23 Herabstufung BofA/Merrill Buy → Neutral
2018-07-10 Bestätigt Chardan Capital Markets Buy
2018-05-09 Bestätigt Barclays Overweight
2018-04-09 Bestätigt Chardan Capital Markets Buy
2018-03-12 Herabstufung Evercore ISI Outperform → In-line
2018-02-13 Eingeleitet Mizuho Neutral
2017-11-09 Fortgesetzt Morgan Stanley Overweight
Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

pulisher
May 27, 2025

REGENXBIO announces royalty monetization agreement for up to $250M - MSN

May 27, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia

May 26, 2025
pulisher
May 26, 2025

REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa

May 26, 2025
pulisher
May 21, 2025

REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.

May 21, 2025
pulisher
May 20, 2025

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria

May 20, 2025
pulisher
May 20, 2025

Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com

May 20, 2025
pulisher
May 20, 2025

Regenxbio Secures $250 Million In New Royalty Bonds - Finimize

May 20, 2025
pulisher
May 19, 2025

REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus

May 19, 2025
pulisher
May 19, 2025

REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus

May 19, 2025
pulisher
May 19, 2025

REGENXBIO secures $150 million to extend cash runway - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

RegenXBio Secures $250M Royalty Monetization Deal - TipRanks

May 19, 2025
pulisher
May 19, 2025

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune

May 19, 2025
pulisher
May 19, 2025

Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan

May 19, 2025
pulisher
May 16, 2025

Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN

May 16, 2025
pulisher
May 15, 2025

REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks

May 15, 2025
pulisher
May 15, 2025

REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®

May 15, 2025
pulisher
May 15, 2025

REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st

May 15, 2025
pulisher
May 14, 2025

Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN

May 14, 2025
pulisher
May 14, 2025

(RGNX) Proactive Strategies - news.stocktradersdaily.com

May 14, 2025
pulisher
May 14, 2025

Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress

May 14, 2025
pulisher
May 14, 2025

US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India

May 13, 2025
pulisher
May 13, 2025

REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Regenxbio stock rises on FDA’s priority review for MPS II therapy By Investing.com - Investing.com South Africa

May 13, 2025
pulisher
May 13, 2025

Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

REGENXBIO Announces FDA Acceptance and Priority Review of the BL - GuruFocus

May 13, 2025

Finanzdaten der Regenxbio Inc-Aktie (RGNX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.06
price up icon 0.95%
$31.31
price up icon 3.40%
$580.95
price up icon 0.82%
$292.90
price up icon 2.57%
$4.64
price up icon 6.67%
$77.49
price up icon 4.82%
Kapitalisierung:     |  Volumen (24h):